Google Groups no longer supports new Usenet posts or subscriptions. Historical content remains viewable.
Dismiss
Pyridoxamine In Diabetes
0 views
Skip to first unread message
ironjustice
Jan 4, 2010, 9:56:13 PM1/4/10
to
Pleiotropic effect of pyridoxamine on diabetic complications via
CD36 expression in KK-A(y)/Ta mice.
Diabetes Res Clin Pract (2009) 0:
M Murakoshi, M Tanimoto, T Gohda, S Hagiwara, I Ohara,
H Toyoda, Y Ishikawa, S Horikoshi, Y Tomino
AIM:
Pyridoxamine inhibits the development of diabetic complications.
CD36 is a receptor/transporter which binds fatty acids of
lipoproteins.
The objective of the present study was to examine the pleiotropic
effects
of pyridoxamine, especially CD36 expression in KK-A(y)/Ta mice with
type 2 diabetic nephropathy.
METHODS:
KK-A(y)/Ta mice were divided into 2 groups as follows: pyridoxamine
treatment group and a tap water group as controls.
The urinary ACR, fasting serum insulin, TG and lipoprotein subclasses
were measured as biochemical parameters.
The renal expressions of malondialdehyde (MDA) were evaluated by
immunohistochemistry.
CD36 mRNA expressions in kidney and adipose tissue were also
evaluated using real-time PCR.
RESULTS:
Pyridoxamine decreased levels of urinary ACR, serum TG, especially
VLDL and fasting serum insulin.
MDA accumulation in the pyridoxamine treated group was significantly
lower than those in the non-treatment group.
The CD36 accumulation and mRNA expressions in kidney and adipose
tissue in the treatment group were significantly higher than those in
the
non-treatment group.
CONCLUSIONS:
It appears that pyridoxamine ameliorated lipid peroxidation and
insulin
resistance in KK-A(y)/Ta mice.
This pleiotropic effect of pyridoxamine was related to CD36
expression
in the kidney and adipose tissue.
-----------
CD36 expression in KK-A(y)/Ta mice.
Diabetes Res Clin Pract (2009) 0:
M Murakoshi, M Tanimoto, T Gohda, S Hagiwara, I Ohara,
H Toyoda, Y Ishikawa, S Horikoshi, Y Tomino
AIM:
Pyridoxamine inhibits the development of diabetic complications.
CD36 is a receptor/transporter which binds fatty acids of
lipoproteins.
The objective of the present study was to examine the pleiotropic
effects
of pyridoxamine, especially CD36 expression in KK-A(y)/Ta mice with
type 2 diabetic nephropathy.
METHODS:
KK-A(y)/Ta mice were divided into 2 groups as follows: pyridoxamine
treatment group and a tap water group as controls.
The urinary ACR, fasting serum insulin, TG and lipoprotein subclasses
were measured as biochemical parameters.
The renal expressions of malondialdehyde (MDA) were evaluated by
immunohistochemistry.
CD36 mRNA expressions in kidney and adipose tissue were also
evaluated using real-time PCR.
RESULTS:
Pyridoxamine decreased levels of urinary ACR, serum TG, especially
VLDL and fasting serum insulin.
MDA accumulation in the pyridoxamine treated group was significantly
lower than those in the non-treatment group.
The CD36 accumulation and mRNA expressions in kidney and adipose
tissue in the treatment group were significantly higher than those in
the
non-treatment group.
CONCLUSIONS:
It appears that pyridoxamine ameliorated lipid peroxidation and
insulin
resistance in KK-A(y)/Ta mice.
This pleiotropic effect of pyridoxamine was related to CD36
expression
in the kidney and adipose tissue.
-----------
FDA Declares Form of Vitamin B6 a Drug, Effectively Banning
Pyridoxamine from Dietary Supplements
Mike Adams
Natural News
Friday, February 13, 2009
The FDA has effectively banned a naturally-occurring form of vitamin
B6 called pyridoxamine by declaring it to be a drug, reports the
American Association for Health Freedom. Responding to a petition
filed by a drug company, the FDA declared pyridoxamine to be “a new
drug.”
------
Who loves ya.
Tom
Jesus Was A Vegetarian!
http://tinyurl.com/2r2nkh
Man Is A Herbivore!
http://tinyurl.com/a3cc3
DEAD PEOPLE WALKING
http://tinyurl.com/zk9fk
0 new messages